2-TUR AUTOIMMUN POLIGLANDULAR SINDROMI UCHUN ERTA MOLEKULYAR VA IMMUN BELGILAR – DIFFERENSIALLASHTIRILGAN TERAPIYANING ASOSI (ADABIYOTLAR SHARHI)
##article.subject##:
2-tur avtoimmun poliglandulyar sindrom, avtoantitanalar, nishonga yo‘naltirilgan terapiya, immunomodulyatsiya, shaxsga yo‘naltirilgan tibbiyot##article.abstract##
2-tur autoimmun poliglandulyar sindrom (APS-2) - bu Addison kasalligi, autoimmun tireoidit va 1-tur qandli diabet kabi avtoimmun patologiyalar bilan tavsiflanadigan murakkab endokrin kasallikdir. APS-2 bo‘yicha olib borilgan ilmiy tadqiqotlarning sezilarli yutuqlariga qaramay, uning patogenezi, diagnostikasi va terapiyasi dolzarb yo‘nalishlardan biri bo‘lib qolmoqda. Ushbu adabiyotlar sharhida kasallikning erta aniqlanishi va prognozini yaxshilashda muhim rol o‘ynaydigan zamonaviy molekulyar va immun markerlar ko‘rib chiqiladi. Genetik moyillik tahlil qilinib, HLA-DR3 va HLA-DR4 allellari, shuningdek, CTLA-4, PTPN22, FOXP3 va STAT4 genlaridagi polimorfizmlar muhokama qilinadi. Bundan tashqari, DNK metillanishi va kodlamaydigan RNKlarning immun mexanizmlarga ta’siri kabi epigenetik omillarga alohida e’tibor qaratiladi. Muhim immun markerlar, jumladan, 21-gidroksilaza, GAD65 va IA-2 ga qarshi autoantitanalar, shuningdek, yallig‘lanish jarayonini kuchaytiruvchi sitokinlar va T-limfotsit populyatsiyasidagi o‘zgarishlar tahlil qilinadi. Differensial terapiya istiqbollari, jumladan, nishonga yo‘naltirilgan monoklonal antitanalar, antigen-spesifik immunoterapiya, hujayraviy texnologiyalar va metabolik regulyatsiya imkoniyatlariga alohida to‘xtalib o‘tiladi. APS-2 mexanizmlarini chuqur o‘rganish kelajakda diagnostika va davolash usullarini takomillashtirishga yordam beradi hamda endokrinologiyada shaxsga yo‘naltirilgan tibbiyot samaradorligini oshirishga xizmat qiladi.
Библиографические ссылки
Barker J.M., Yu L., Eisenbarth G.S. Autoantibodies in diabetes. Diabetes Care. 2019;42(5):869-876.
Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: New insights. Journal of Endocrinological Investigation. 2018;41(8):865-875.
Dendrou C.A., Petersen J., Rossjohn J. Role of CD25 in autoimmune diseases: A new insight. Trends in Immunology. 2023;44(2):124-136.
Gianchecchi E., Fierabracci A. Insights into the role of epigenetics in autoimmune diseases. Frontiers in Immunology. 2022;13:875212.
Gonzalez F.J., Strowig T., Flavell R.A. Peptide-based immunotherapy for autoimmune diseases. Nature Reviews Drug Discovery. 2023;22(1):34-50.
Husebye E.S., Anderson M.S., Kampe O. Autoimmune polyendocrine syndromes. The New England Journal of Medicine. 2020;382(12):1133-1144.
Husebye E.S., Perheentupa J., Rautemaa R. Autoimmune polyendocrinopathy syndromes and immune deficiency. Endocrine Reviews. 2022;43(3):467-492.
Johnson M.B., Kawakami T., Takahashi Y. IL-2 receptor and immune regulation in endocrine autoimmunity. Cellular & Molecular Immunology. 2021;18(5):1156-1165.
Kahles H.K., Heinig B., Mandrup-Poulsen T. CTLA-4 and its role in autoimmune endocrine diseases. Nature Reviews Endocrinology. 2019;15(2):89-103.
Kahles H.K., Peters B., Mandrup-Poulsen T. Autoimmune endocrine diseases and checkpoint inhibitors. Trends in Endocrinology & Metabolism. 2023;34(2):89-102.
Kawasaki E., Eguchi K. Molecular and genetic bases of type 1 diabetes in Japanese population. Journal of Diabetes Investigation. 2022;13(4):735-748.
Myers P., Gianchecchi E., Fierabracci A. Genetic and epigenetic patterns in autoimmune polyendocrine syndromes. Frontiers in Endocrinology. 2021;12:647632.
Simmonds M.J., Gough S.C.L. The role of viral infections in autoimmune disease. Current Opinion in Immunology. 2021;73:10-16.
Smith A.G., Clark P., Li X. Epigenetic modifications in autoimmunity: New insights. Frontiers in Genetics. 2022;13:765987.
Wang L., Zhang H., Xiao X. Role of TET2 in immune tolerance and autoimmunity. Immunological Reviews. 2023;310(1):72-87.
Wang X., Chen J., Xu Y. Regulatory T cell therapy in autoimmune endocrine diseases. Immunotherapy. 2023;15(2):97-112.
Wu C., Yu X., Liu J. The metabolic pathways in autoimmune endocrinopathies. Metabolism. 2023;140:155347.
Wu H., Esteve E., Tremaroli V. The gut microbiota in endocrine disorders. Nature Reviews Endocrinology. 2023;19(3):151-167.
Wu H.J., Ivanov I.I., Darce J. Gut microbiota and systemic autoimmunity. Immunity. 2023;58(6):1065-1079.
Zhang J., Liu Y., Zhao X. MicroRNA regulation in autoimmune diseases: A new therapeutic strategy? Autoimmunity Reviews. 2023;22(5):102713.
Zhang L., Feng Y., Lu Y. PD-1 blockade therapy and its impact on autoimmune endocrinopathies. Clinical Endocrinology. 2022;97(4):488-497.
Zhang Q., Wang Y., Zhu L. Autoantibodies in autoimmune polyglandular syndromes: Pathogenic significance. Journal of Autoimmunity. 2023;135:102989.
Zhao W., Li J., Wang S. Role of pro-inflammatory cytokines in autoimmune endocrine diseases. Journal of Clinical Immunology. 2022;42(4):765-779.
